Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2014 1
2019 3
2022 7
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis.
Soe KK, Krikeerati T, Pheerapanyawaranun C, Niyomnaitham S, Phinyo P, Thongngarm T. Soe KK, et al. Among authors: niyomnaitham s. Front Pharmacol. 2023 May 23;14:1184552. doi: 10.3389/fphar.2023.1184552. eCollection 2023. Front Pharmacol. 2023. PMID: 37288109 Free PMC article. Review.
Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women.
Chayachinda C, Watananirun K, Phatihattakorn C, Anuwutnavin S, Niyomnaitham S, Phongsamart W, Lapphra K, Wittawatmongkol O, Rungmaitree S, Jansarikit L, Boonnak K, Wongprompitak P, Senawong S, Upadhya A, Toh ZQ, Licciardi PV, Chokephaibulkit K. Chayachinda C, et al. Among authors: niyomnaitham s. Hum Vaccin Immunother. 2023 Aug 1;19(2):2228670. doi: 10.1080/21645515.2023.2228670. Epub 2023 Jul 13. Hum Vaccin Immunother. 2023. PMID: 37439770 Free PMC article. Clinical Trial.
Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
Wittawatmongkol O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, Boonsathorn S, Chantasrisawad N, Sudjaritruk T, Niyomnaitham S, Senawong S, Srisutthisamphan K, Quan Toh Z, Rungmaitree S, Nanthapisal S, Phanthanawiboon S, Khantee P, Techasaensiri C, Hirankarn N, Pangprasertkul S, Chokephaibulkit K. Wittawatmongkol O, et al. Among authors: niyomnaitham s. Vaccine. 2023 Sep 15;41(40):5834-5840. doi: 10.1016/j.vaccine.2023.08.021. Epub 2023 Aug 14. Vaccine. 2023. PMID: 37586956 Free article. Clinical Trial.
Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial.
Niyomnaitham S, Toh ZQ, Licciardi PV, Wongprompitak P, Srisutthisamphan K, Copeland KK, Chokephaibulkit K. Niyomnaitham S, et al. J Infect. 2022 Oct;85(4):436-480. doi: 10.1016/j.jinf.2022.06.014. Epub 2022 Jun 18. J Infect. 2022. PMID: 35728642 Free PMC article. Clinical Trial. No abstract available.
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study.
Sirijatuphat R, Manosuthi W, Niyomnaitham S, Owen A, Copeland KK, Charoenpong L, Rattanasompattikul M, Mahasirimongkol S, Wichukchinda N, Chokephaibulkit K. Sirijatuphat R, et al. Among authors: niyomnaitham s. Emerg Microbes Infect. 2022 Dec;11(1):2197-2206. doi: 10.1080/22221751.2022.2117092. Emerg Microbes Infect. 2022. PMID: 35997325 Free PMC article. Clinical Trial.
Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination.
Chatsiricharoenkul S, Niyomnaitham S, Posen HJ, Toh ZQ, Licciardi PV, Wongprompitak P, Duangchinda T, Pakchotanon P, Chantima W, Chokephaibulkit K. Chatsiricharoenkul S, et al. Among authors: niyomnaitham s. Front Immunol. 2022 Oct 4;13:1010835. doi: 10.3389/fimmu.2022.1010835. eCollection 2022. Front Immunol. 2022. PMID: 36268028 Free PMC article.
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham S, Quan Toh Z, Wongprompitak P, Jansarikit L, Srisutthisamphan K, Sapsutthipas S, Jantraphakorn Y, Mingngamsup N, Licciardi PV, Chokephaibulkit K. Niyomnaitham S, et al. Hum Vaccin Immunother. 2022 Nov 30;18(6):2091865. doi: 10.1080/21645515.2022.2091865. Epub 2022 Jul 11. Hum Vaccin Immunother. 2022. PMID: 35816053 Free PMC article. Clinical Trial.
19 results